Late onset pancytopenia post chimeric antigen receptor T cell therapy triggered by a COVID-19 vaccination: a case report
Cytopenia is a common side effect after chimeric antigen receptor T cell (CAR-T) therapy but is unusual at late timepoints when it is most commonly due to bone marrow (BM) failure, myelodysplasia (MDS) or other secondary malignancies. In this case report, we describe a patient who developed severe aplastic anaemia 18 months after CD19 CAR-T therapy, and shortly after COVID-19 vaccination. This is the first description of severe aplastic anaemia triggered by COVID-19 vaccination as a cause of post-CAR-T cytopenia. The patient described was treated with a combination of eltrombopag and ciclosporin due to frailty and had a rapid and complete clinical response to this therapy, providing an effective option for the treatment of immune-related cytopenia post-CAR-T in an increasingly elderly and frail population.
Authors
- Anna Childerhouse
- Paul Maciocia (ORCID: https://orcid.org/0000-0002-9757-8073)
- Claire Roddie (ORCID: https://orcid.org/0000-0002-4901-5858)
- Maeve A O'Reilly (ORCID: https://orcid.org/0000-0002-2702-397X)
- Dean Spencer
- Nicola Maciocia (ORCID: https://orcid.org/0000-0002-3865-3723)
- Elspeth M. Payne (ORCID: https://orcid.org/0000-0001-5841-778X)
Institutions
- University College London Hospitals NHS Foundation Trust (GB)
- London Cancer (GB)
- University College London (GB)
Publication Details
- Journal
- Frontiers in Hematology
- Published
- 2024-11-15
- DOI
- https://doi.org/10.3389/frhem.2024.1435584
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00